JAAD case reports
Cure8 research brief
Limited source text
What Cure8 can confirm
What We Know
Cure8 does not have enough reliable source text to summarize this article yet. Based on the article title and source metadata, this appears to be a case report related to Crohn's disease, Upadacitinib, JAK inhibitor, and Medications. Use the original source link for the full details.
What Is Not Available
The source did not provide enough reliable article text for a source-grounded Cure8 brief. Study details, results, and limitations should be checked in the original source.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationJAAD case reports
AuthorsNoot CH, Beck EP, Clarke JT +1 more
Study typeJournal article, case reports
Indexed viaEurope PMC
Source typeResearch paper
PublishedJun 3, 2026, 12:00 AM
Content availableMetadata only
Cure8 could not retrieve enough reliable source text to summarize this article. This page is based on the article title, source metadata, and Cure8 topic classification.
Upadacitinib shows year-long benefit in perianal Crohn's disease
Based on the title and source metadata, this appears to be a clinical trial phase 3 related to Crohn's disease, Inflammatory bowel disease, and Upadacitinib. The original article is from msn.com.
Upadacitinib Shows Efficacy in Refractory Crohn's Disease - Medscape
This study reports that upadacitinib produced clinical responses and steroid-free remission in a majority of patients with refractory Crohn's disease at 12 weeks, which may be relevant for people who have not responded...
Upadacitinib Effective for Perianal Crohn's Disease | Docwire News
The study suggests upadacitinib may improve both symptoms and MRI‑documented healing of perianal fistulas in Crohn’s disease, offering a potential treatment option especially for patients who have not previously received...